

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/LO/044	198164	A Phase 2 Study of LY2606368 in patients with extensive stage disease small cell lung cancer.	Number Agreed	2	2	Date Agreed	18/01/2017	1	18/01/2017	1	Recruitment Finished
16/SC/033	208403	Utilizing Novel dipole density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER-AF)	Number Agreed	10	10	Date Agreed	01/03/2017	1	01/03/2017	1	Recruitment Finished
17/EE/002	221514	A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ARE INELIGIBLE	Number Agreed	5	5	Date Agreed	29/06/2017	0	29/06/2017	0	Recruitment Finished
15/LO/150	187068	Investigation of drug-drug interaction between nintedanib and pirfenidone in patients with IPF (an open label, multiple-dose, two group study)	Number Agreed	4	4	Date Agreed	06/03/2017	3	06/03/2017	3	Recruitment Finished
14/WM/10	158411	A Placebo Controlled, Double-blind, Multi-centre, Repeat Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery	Not Available / Not Agreed			Date Agreed	01/11/2017	0	01/11/2017	0	Recruitment Finished
14/EM/014	152568	A multi-centre, open-label, study of Mepolizumab in a subset of subjects with a history of life threatening/seriously debilitating asthma who participated in the MEA115661 Trial	Number Agreed	6	6	Date Agreed	10/01/2017	5	10/01/2017	5	Recruitment Finished
16/EE/004	192528	A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjects with partially controlled or uncontrolled asthm	Number Agreed	7	7	Date Agreed	28/04/2017	4	28/04/2017	4	Recruitment Finished
16/EE/001	194393	A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 EFFICACY AND SAFETY STUDY OF OTO-104 GIVEN ASA SINGLE INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE	Number Agreed	3	3	Date Agreed	31/05/2017	3	31/05/2017	3	Recruitment Finished
15/SC/070	192904	Clinical Study Protocol M13-549A Phase 3, randomized, double-blind study comparing ABT-494 to placebo in subjects with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic disease-modifying anti-rheum	Number Agreed	4	4	Date Agreed	12/09/2017	0	12/09/2017	0	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/NW/040	182025	A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia	Number Agreed	3	3	Date Agreed	13/03/2017	3	13/03/2017	3	Recruitment Finished
14/WS/114	166537	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (E	Number Agreed	10	10	Date Agreed	20/09/2017	7	20/09/2017	7	Recruitment Finished
14/EM/106	152584	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	Number Agreed	1	1	Date Agreed	20/01/2017	2	20/01/2017	2	Recruitment Finished
17/EM/019	219055	A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes	Number Agreed	10	10	Date Agreed	11/10/2019	0	31/12/2017	0	Withdrawn By Sponsor
16/LO/138	199366	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Congestion due to Heart Failure	Number Agreed	6	6	Date Agreed	17/11/2017	1	17/11/2017	1	Recruitment Finished
13/NE/000	100377	Product Surveillance Registry A prospective, noninterventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic marketreleased products within diabetes, cardia	Number Agreed	5	5	Date Agreed	03/07/2017	3	03/07/2017	3	Recruitment Finished
17/LO/050	224298	An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma	Number Agreed	2	2	Date Agreed	07/02/2018	2	11/08/2017	2	Recruitment Finished
11/SC/0059	74662	INCA 2201, INC 424 - A Phase IB, Open-Label, Dose-Finding Study Of The JAK-inhibitor INC424 Tablets Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) Or Post-Essential Thrombocythemia-Myel	Number Agreed	2	2	Date Agreed	13/01/2017	0	13/01/2017	0	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/NW/016	196447	An open-label, randomised, phase II study comparing TAS-102 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are eligible for non-intensive therapy	Number Agreed	12	12	Date Agreed	27/02/2017	2	27/02/2017	2	Recruitment Finished
16/EM/016	203281	A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer	Number Agreed	9	9	Date Agreed	28/07/2017	4	28/07/2017	4	Recruitment Finished
15/LO/123	183416	A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis	Number Agreed	2	2	Date Agreed	18/05/2017	0	18/05/2017	0	Recruitment Finished
14/SC/116	155743	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Number Agreed	100	100	Date Agreed	10/08/2017	100	10/08/2017	100	Recruitment Finished
15/LO/054	172357	Clinical and device functional assessment of real world ICD patients - RTSY03	Number Agreed	10	10	Date Agreed	31/10/2017	11	31/10/2017	11	Recruitment Finished
16/EM/000	190428	Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based	Number Agreed	12	12	Date Agreed	02/10/2017	4	02/10/2017	4	Recruitment Finished
15/NW/015	169540	A multicenter, open-label, single-arm safety study of Herceptin Subcutaneous in combination with Perjeta and Docetaxel in treatment of patients with HER2-Positive advanced breast cancer (metastatic or locally recurrent)	Number Agreed	15	15	Date Agreed	03/02/2017	3	03/02/2017	3	Recruitment Finished
16/NW/004	197706	SOLAR-1: A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and post-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer which progressed on or after arom	Number Agreed	8	8	Date Agreed	10/06/2017	3	10/06/2017	3	Recruitment Finished
15/WA/046	189501	Expanding MRI Access for Patients with New and Existing ICDs and CRT-Ds	Number Agreed	10	10	Date Agreed	10/08/2017	10	10/08/2017	10	Recruitment Finished
16/YH/011	198679	Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy: ACE-CL-208	Number Agreed	2	2	Date Agreed	21/08/2017	0	21/08/2017	0	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/LO/145	202124	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Na?ve to Proteasome Inhibitors	Number Agreed	6	6	Date Agreed	17/05/2017	6	17/05/2017	6	Recruitment Finished
15/NW/045	181246	A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia	Number Agreed	5	5	Date Agreed	30/06/2017	2	30/06/2017	2	Recruitment Finished
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced	Number Agreed	5	5	Date Agreed	16/10/2017	2	16/10/2017	2	Recruitment Finished
16/LO/171	212505	A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator?s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia	Number Agreed	3	3	Date Agreed	25/10/2017	0	25/10/2017	0	Recruitment Finished
15/EM/034	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma	Number Agreed	5	5	Date Agreed	13/01/2017	8	13/01/2017	8	Recruitment Finished
15/LO/210	192155	RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY EVALUATING TAS-102 PLUS	Number Agreed	4	4	Date Agreed	30/11/2017	3	30/11/2017	3	Recruitment Finished